ClinicalTrials.gg
CompletedNCT02804750Updated Oct 15, 2019Results posted

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

A Phase 2 interventional study of CORT125134 in Cushing's Syndrome, sponsored by Corcept Therapeutics. Completed at 25 sites in 5 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-10-15.

Sponsored by Corcept Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies in Cushing Syndrome by Corcept Therapeutics — none open to participants now, 1 under way, none of them phase 3. Cushing Syndrome · Corcept Therapeutics.

Enrollment
6th of 11
35 · median 35
Started
2016
with 1 other
Phase 2
2 of 16
none open now
Registered
7th of 16
by date

Among the 16 studies in Cushing Syndrome by Corcept Therapeutics, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2016, is one of 2 in phase 2, and was the 7th registered.

Cushing Syndrome

123 studies on the registry are indexed under Cushing Syndrome; 42 are open to participants now.

Browse Cushing Syndrome studies →

Open to participants now

None of the 16 studies in Cushing Syndrome by Corcept Therapeutics is open now. The open studies under Cushing Syndrome, anywhere →

Who these studies take

Of the 35 Cushing Syndrome studies recruiting now, 14 (40%) set no upper age limit and 10 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Cushing Syndrome by Corcept Therapeutics as a file.
02

Study summary

Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol. Endogenous Cushing's syndrome resulting from cortisol overproduction by the adrenal glands is the subject of this protocol.

Patients with exogenous Cushing's syndrome, which develops as a side effect of chronic administration of high doses of glucocorticoids, were not eligible for enrollment in this study.

The purpose of this study was to evaluate the safety and efficacy of CORT125134 for treatment of endogenous Cushing's syndrome. The multicenter study was conducted in the United States and in Europe.

Read the detailed description

This was a Phase 2, open-label study with two dose groups, each with a two-step dose escalation, designed to evaluate the safety and efficacy of CORT125134 for the treatment of endogenous Cushing's syndrome. CORT125134 was administered orally once daily for 16 weeks with dose escalations occurring every 4 weeks.

Pharmacokinetics (PK) profiles were generated at every dose level. A data review committee reviewed PK and safety data and recommended the final plan for dose escalation in Group 2.

03

Conditions studied

  • Cushing's Syndrome

Keywords

  • Cushing's Syndrome
  • Cushing's Disease
  • Cushing's
  • Hypercortisolemia
  • Cushingoid
  • Type 2 Diabetes
  • Impaired Glucose Intolerance
  • Hypertension
  • Adrenal Corticotrophic Hormone (ACTH)
  • Adrenocortical Carcinoma
  • Primary Pigmented Nodular Adrenal Disease (PPNAD)
  • Moon Facies
  • Dorsocervical Fat Pad
  • Adrenal Adenoma
  • Adrenal Carcinoma
  • Adrenal Autonomy
  • Cortisol
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has a confirmed diagnosis of endogenous Cushing's syndrome.
  2. Requires medical treatment of hypercortisolemia.
  3. Meets at least one of the following criteria:

    1. Has type 2 diabetes mellitus.
    2. Has impaired glucose tolerance.
    3. Has hypertension.

Exclusion criteria

Exclusion Criteria:

  1. Has non-endogenous source of hypercortisolemia
  2. Has uncontrolled, hypothyroidism or hyperthyroidism
  3. Has poorly controlled hypertension
  4. Has Stage ≥ 4 renal failure
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Group 1: Low-dose Group

    100 mg/day for 4 weeks in Period 1, then 150 mg/day for 4 weeks in Period 2, then 200 mg/day for 4 weeks in Period 3. There was no washout between treatment periods. Period 3 was followed by a 4-week follow-up period. Per-protocol, Group 1 did not participate in treatment Period 4.

    Drug: CORT125134

  • Experimental
    Group 2: High-dose Group

    250 mg/day for 4 weeks in Period 1, then 300 mg/day for 4 weeks in Period 2, then 350 mg/day for 4 weeks in Period 3, then 400 mg/day for 4 weeks in Period 4. There was no washout between treatment periods. Period 4 was followed by a 4-week follow-up period.

    Drug: CORT125134

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With One or More Adverse Events

    All treatment-emergent adverse events were recorded and summarized.

    Time frame: Group 1: up to Week 16; Group 2: up to Week 20

  2. Percentage of Participants With One or More Severe (≥Grade 3) Adverse Events

    All treatment-emergent adverse events with Common Terminology Criteria for Adverse Events (CTCAE) ≥Grade 3 (severe) were recorded and summarized.

    Time frame: Group 1: up to Week 16; Group 2: up to Week 20

Secondary outcomes

  1. Percentage of Participants With Hypertension Who Experience Improvement in Blood Pressure Following Treatment With CORT125134

    Improvement in blood pressure was defined as a participant who experiences at least a 5 mmHg decrease in mean diastolic or systolic BP from baseline who has not taken an additional antihypertensive medication during the treatment period or increased the dosage of a concurrent antihypertensive medication.

    Time frame: Group 1: Week 12 or last observation; Group 2: Week 16 or last observation

  2. Percentage of Participants With IGT / T2DM Who Experienced a ≥25% Reduction in AUCglucose Following Treatment With CORT125134

    Improvement in glucose control was defined as a participant who experiences at least a 25% decrease from baseline in area under the concentration-time curve for blood glucose (AUCglucose) who has not taken an additional diabetes medication during the treatment period or increased the dosage of a concurrent diabetes medication.

    Time frame: Before and 0.5, 1, 1.5, and 2 hours after a glucose drink at Week 12 or last observation (Group 1) or Week 16 or last observation (Group 2)

07

Results

Posted Sep 25, 2019

Participant flow

All enrolled participants who received at least 1 dose of study drug

Period 1
Participant flow — Period 1
MilestoneGroup 1: Low-dose GroupGroup 2: High-dose Group
Started1718
Completed1715
Not completed03
Withdrew: Adverse event02
Withdrew: Withdrawal by subject01
Period 2
Participant flow — Period 2
MilestoneGroup 1: Low-dose GroupGroup 2: High-dose Group
Started1715
Completed1615
Not completed10
Withdrew: Adverse event10
Period 3
Participant flow — Period 3
MilestoneGroup 1: Low-dose GroupGroup 2: High-dose Group
Started1615
Completed1613
Not completed02
Withdrew: Adverse event02
Period 4
Participant flow — Period 4
MilestoneGroup 1: Low-dose GroupGroup 2: High-dose Group
Started012
Completed07
Not completed05
Withdrew: Adverse event05

Outcome measures

PrimaryPercentage of Participants With One or More Adverse Events

All treatment-emergent adverse events were recorded and summarized.

Time frame:
Group 1: up to Week 16; Group 2: up to Week 20
Reported as:
Count of participants · Participants
Percentage of Participants With One or More Adverse Events
ParticipantsGroup 1: Low-dose GroupGroup 2: High-dose Group
Percentage of Participants With One or More Adverse Events1518
PrimaryPercentage of Participants With One or More Severe (≥Grade 3) Adverse Events

All treatment-emergent adverse events with Common Terminology Criteria for Adverse Events (CTCAE) ≥Grade 3 (severe) were recorded and summarized.

Time frame:
Group 1: up to Week 16; Group 2: up to Week 20
Reported as:
Count of participants · Participants
Percentage of Participants With One or More Severe (≥Grade 3) Adverse Events
ParticipantsGroup 1: Low-dose GroupGroup 2: High-dose Group
Percentage of Participants With One or More Severe (≥Grade 3) Adverse Events37
SecondaryPercentage of Participants With Hypertension Who Experience Improvement in Blood Pressure Following Treatment With CORT125134

Improvement in blood pressure was defined as a participant who experiences at least a 5 mmHg decrease in mean diastolic or systolic BP from baseline who has not taken an additional antihypertensive medication during the treatment period or increased the dosage of a concurrent antihypertensive medication.

Time frame:
Group 1: Week 12 or last observation; Group 2: Week 16 or last observation
Reported as:
Number · Percentage of participants
Percentage of Participants With Hypertension Who Experience Improvement in Blood Pressure Following Treatment With CORT125134
Percentage of participantsGroup 1: Low-dose GroupGroup 2: High-dose Group
Percentage of Participants With Hypertension Who Experience Improvement in Blood Pressure Following Treatment With CORT12513441.67 (15.17 to 72.33)63.64 (30.79 to 89.07)
SecondaryPercentage of Participants With IGT / T2DM Who Experienced a ≥25% Reduction in AUCglucose Following Treatment With CORT125134

Improvement in glucose control was defined as a participant who experiences at least a 25% decrease from baseline in area under the concentration-time curve for blood glucose (AUCglucose) who has not taken an additional diabetes medication during the treatment period or increased the dosage of a concurrent diabetes medication.

Time frame:
Before and 0.5, 1, 1.5, and 2 hours after a glucose drink at Week 12 or last observation (Group 1) or Week 16 or last observation (Group 2)
Reported as:
Number · Percentage of participants
Percentage of Participants With IGT / T2DM Who Experienced a ≥25% Reduction in AUCglucose Following Treatment With CORT125134
Percentage of participantsGroup 1: Low-dose GroupGroup 2: High-dose Group
Percentage of Participants With IGT / T2DM Who Experienced a ≥25% Reduction in AUCglucose Following Treatment With CORT12513423.08 (5.04 to 53.81)0 (0 to 23.16)
Post-hocPercentage of Participants With IGT / T2DM Who Experienced Improvement in Glucose Control Following Treatment With CORT125134: Responder Definition Based on Response Criteria for Phase 3 Study NCT03697109

Improvement in glucose control was defined based on response criteria for Phase 3 study NCT03697109: a participant who experiences 1) a hemoglobin A1c (HbA1c) that is decreased by ≥ 0.5% from baseline, 2) a 2-hour oGTT plasma glucose that is normalized (\< 7.8 mmol/L) or decreased by ≥ 2.8 mmol/L from baseline, or 3) a total daily insulin dose that has decreased by ≥ 25% or total daily sulfonylurea dose that has decreased by ≥ 50% and an HbA1c that is unchanged or decreased from baseline.

Time frame:
Before and 0.5, 1, 1.5, and 2 hours after a glucose drink at Week 12 or last observation (Group 1) or Week 16 or last observation (Group 2)
Reported as:
Number · Percentage of participants
Percentage of Participants With IGT / T2DM Who Experienced Improvement in Glucose Control Following Treatment With CORT125134: Responder Definition Based on Response Criteria for Phase 3 Study NCT03697109
Percentage of participantsGroup 1: Low-dose GroupGroup 2: High-dose Group
Percentage of Participants With IGT / T2DM Who Experienced Improvement in Glucose Control Following Treatment With CORT125134: Responder Definition Based on Response Criteria for Phase 3 Study NCT0369710915.38 (1.92 to 45.45)50.00 (21.09 to 78.91)

Adverse events

Collected over Group 1: up to Week 16; Group 2: up to Week 20. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Low-dose Group0/17 (0%)0/17 (0%)15/17 (88.2%)
Group 2: High-dose Group0/18 (0%)4/18 (22.2%)18/18 (100%)
Most frequent serious events
Most frequent serious events
EventGroup 1: Low-dose GroupGroup 2: High-dose Group
Pilonidal cystInfections and infestations0/171/18
MyopathyMusculoskeletal and connective tissue disorders0/171/18
Acute myocardial infarctionCardiac disorders0/171/18
HypertensionVascular disorders0/171/18
PolyneuropathyNervous system disorders0/171/18
Most frequent other events
Showing 10 of 112
Most frequent other events
EventGroup 1: Low-dose GroupGroup 2: High-dose Group
Back painMusculoskeletal and connective tissue disorders4/177/18
NauseaGastrointestinal disorders3/175/18
Oedema peripheralGeneral disorders4/175/18
HeadacheNervous system disorders4/175/18
DiarrhoeaGastrointestinal disorders4/173/18
Pain in extremityMusculoskeletal and connective tissue disorders4/174/18
DyspepsiaGastrointestinal disorders1/174/18
Abdominal painGastrointestinal disorders0/174/18
ArthralgiaMusculoskeletal and connective tissue disorders2/174/18
MyalgiaMusculoskeletal and connective tissue disorders1/174/18

Baseline characteristics

All enrolled participants who received at least 1 dose of study drug

Age, Continuous
Age, Continuous(years)Group 1: Low-dose GroupGroup 2: High-dose GroupTotal
Mean47.6 ± 13.6249.5 ± 13.4648.6 ± 13.37
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Low-dose GroupGroup 2: High-dose GroupTotal
Female91625
Male8210
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: Low-dose GroupGroup 2: High-dose GroupTotal
Hispanic or Latino123
Not Hispanic or Latino161632
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: Low-dose GroupGroup 2: High-dose GroupTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White171835
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Group 1: Low-dose GroupGroup 2: High-dose GroupTotal
Netherlands202
Hungary325
United States3912
Italy7714
United Kingdom202
Hypertension
Hypertension(Participants)Group 1: Low-dose GroupGroup 2: High-dose GroupTotal
Count of participants121123
Impaired Glucose Tolerance (IGT) / Type-2 Diabetes Mellitus (T2DM)
Impaired Glucose Tolerance (IGT) / Type-2 Diabetes Mellitus (T2DM)(Participants)Group 1: Low-dose GroupGroup 2: High-dose GroupTotal
Count of participants131528
08

Study locations

25 sites
  • Laguna Hills, California 92653, United States
  • Aurora, Colorado 80045, United States
  • Fort Lauderdale, Florida 33312, United States
  • Miami, Florida 33136, United States
  • Indianapolis, Indiana 46202, United States
  • Covington, Kentucky 41011, United States
  • Rochester, Minnesota 55905, United States
  • Saint Louis, Missouri 63110, United States
  • New York, New York 10016, United States
  • Cleveland, Ohio 44195, United States
  • Pittsburgh, Pennsylvania 15212, United States
  • Richmond, Virginia 23119, United States
  • Budapest, Hungary
  • Pecs, Hungary
  • Cuneo, Italy
  • Messina, Italy
  • Milano, Italy
  • Naples, Italy
  • Orbassano, Italy
  • Roma, Italy
  • Siena, Italy
  • Torino, Italy
  • Leiden, Netherlands
  • Rotterdam, Netherlands
  • Salford, Manchester, United Kingdom
09

References and documents

Publications

  • Pivonello R, Munster PN, Terzolo M, Ferrigno R, Simeoli C, Puglisi S, Bali U, Moraitis AG. Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant. Front Endocrinol (Lausanne). 2022 Jan 4;12:793262. doi: 10.3389/fendo.2021.793262. eCollection 2021. PubMed 35058882 ↗
  • Pivonello R, Bancos I, Feelders RA, Kargi AY, Kerr JM, Gordon MB, Mariash CN, Terzolo M, Ellison N, Moraitis AG. Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study. Front Endocrinol (Lausanne). 2021 Jul 14;12:662865. doi: 10.3389/fendo.2021.662865. eCollection 2021. Erratum In: Front Endocrinol (Lausanne). 2022 Apr 27;13:899616. doi: 10.3389/fendo.2022.899616. PubMed 34335465 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2016 to primary completion in Sep 2018, 27 months.

Results were first posted in Sep 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2016
First posted
Jun 17, 2016
StartActual
Jun 2016
Primary completionActual
Sep 2018
CompletionActual
Sep 2018
Results first posted
Sep 25, 2019
Last update
Oct 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02804750
Responsible party
Sponsor
First posted
Jun 17, 2016
Start date
Jun 2016
Primary completion
Sep 2018
Completion
Sep 2018
Results posted
Sep 25, 2019
Last update
Oct 15, 2019

Study contacts

Andreas G Moraitis, MD
study director · Corcept Therapeutics

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relacorilant

Start the discussion